TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016

  • ID: 3802793
  • Drug Pipelines
  • 46 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biogen, Inc.
  • ImStar Therapeutics Inc.
  • Primary Peptides, Inc.
  • TauRx Therapeutics Ltd.
  • MORE
TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016

Summary

‘TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016’, provides in depth analysis on TAR DNA-Binding Protein 43 (TDP-43) targeted pipeline therapeutics.

The report provides comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for TAR DNA-Binding Protein 43 (TDP-43)
- The report reviews TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics and enlists all their major and minor projects
- The report assesses TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for TAR DNA-Binding Protein 43 (TDP-43)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding TAR DNA-Binding Protein 43 (TDP-43) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen, Inc.
  • ImStar Therapeutics Inc.
  • Primary Peptides, Inc.
  • TauRx Therapeutics Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

TAR DNA-Binding Protein 43 (TDP-43) Overview

Therapeutics Development

TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Stage of Development

TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Therapy Area

TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Indication

TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Products Glance

Late Stage Products

Early Stage Products

TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Companies

TAR DNA-Binding Protein 43 (TDP-43) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

TAR DNA-Binding Protein 43 (TDP-43) - Companies Involved in Therapeutics Development

Biogen, Inc.

ImStar Therapeutics Inc.

Primary Peptides, Inc.

SK Biopharmaceuticals Co., Ltd.

TauRx Therapeutics Ltd.

TAR DNA-Binding Protein 43 (TDP-43) - Drug Profiles

IMS-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRx-0237 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAR DNA-Binding Protein 43 (TDP-43) - Dormant Projects

TAR DNA-Binding Protein 43 (TDP-43) - Featured News & Press Releases

Nov 23, 2015: Aquinnah Pharmaceuticals Receives $680,000 Grant from NINDS To Advance New Therapies for ALS

Jan 20, 2015: First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease

Sep 25, 2014: Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy

Sep 22, 2014: TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX in Alzheimer's Disease

Jul 15, 2014: TauRx Therapeutics Achieves Enrolment Target in the First of Its Two Phase III Clinical Trials of LMTX in Alzheimer’s Disease

Jun 18, 2014: University Hospitals Case Medical Center now enrolling patients in clinical trial for Frontotemporal Dementia

Mar 27, 2014: TauRx Chairman to present at scientific symposium focused on advances in Alzheimer's treatments

Mar 24, 2014: TauRx Therapeutics to present at Social Care Conference in London on 25th

Jan 09, 2014: First German Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease

Jan 06, 2014: TauRx Expands Alzheimer's Clinical Trials in the United States

Nov 26, 2013: ImStar Therapeutics Selects Lead Drug Candidate for ALS

Oct 03, 2013: Professor Claude Wischik, Chairman of TauRx, highlights future consequences of Alzheimer’s Disease at annual psychogeriatric conference in Korea

Sep 19, 2013: TauRx achieves milestone in global Phase 3 clinical trials of LMTX for Alzheimer's Disease

Jun 10, 2013: TauRx Therapeutics And Toronto Memory Program Announce Canadian Launch Of Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease

May 22, 2013: TauRx Therapeutics Enrolls First Patient In Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease In UK

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 46List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Biogen, Inc., H1 2016

Pipeline by ImStar Therapeutics Inc., H1 2016

Pipeline by Primary Peptides, Inc., H1 2016

Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016

Pipeline by TauRx Therapeutics Ltd., H1 2016

Dormant Projects, H1 2016 33List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Biogen, Inc.
  • ImStar Therapeutics Inc.
  • Primary Peptides, Inc.
  • TauRx Therapeutics Ltd.
  • MORE
TAR DNA-Binding Protein 43 (TDP-43) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.The author's latest report TAR DNA-Binding Protein 43 - Pipeline Review, H1 2016, outlays comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

TAR DNA-Binding Protein 43 (TDP-43) TAR DNA-binding protein 43 or TDP-43 is a protein encoded by the TARDBP gene. It is involved in the regulation of CFTR splicing, microRNA biogenesis, apoptosis and cell division. It represses HIV-1 transcription by binding to the HIV-1 long terminal repeat. It stabilizes the low molecular weight neurofilament mRNA through a direct interaction with the 3' UTR. The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 3 respectively.

Furthermore, this report also reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Biogen, Inc.
ImStar Therapeutics Inc.
Primary Peptides, Inc.
SK Biopharmaceuticals Co., Ltd.
TauRx Therapeutics Ltd.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll